A new study shows an experimental heart-pump device being developed by HeartWare (HTWR +22.6%)...

|By:, SA News Editor

A new study shows an experimental heart-pump device being developed by HeartWare (HTWR +22.6%) was able to keep more than 90% of patients alive six months after receiving the device, and worked as well as other heart-pumping devices such as one by Thoratec (THOR -20%).